|
|
|
|
|
|
|
M T W Thu F |
|
30 April, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Although Eli Lilly's first-quarter earnings exceeded expectations, everyone wants to know about its new obesity pill Foundayo. CEO David Ricks said this morning that Lilly still needs time to build the brand. “Doctors aren’t going to write medicine they’ve never heard of,” he told CNBC. Read more here from Elizabeth Cairns, who continues to provide comprehensive obesity coverage. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Gelman
|
Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
About 20,000 people are taking Foundayo, Eli Lilly’s obesity pill, after its first 20 days on the market, according to the company’s CEO David Ricks... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is sellingover 16.5 million shares at $18 apiece. The company is set to start trading... | |
|
|
|
|
|
|
|
|
by Ngai Yeung
|
CVS Health has been testing AI tools that deliver healthcare, though it sees too many barriers to using them more widely for now. CVS' President... | |
|
|
|
|
|
